NCT04697888View on ClinicalTrials.gov

Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Parenteral Nutrition-related Hepatitis
Interventions
DRUG

Omegaven

Expanded Access Therapy with Omegaven will be initiated at a starting dose of 0.5 gm/kg/day to be infused over 24 hrs. After two days of infusion the dose will be increased to 1gm/kg/day.

Trial Locations (1)

64108

Children's Mercy Hospitals and Clinics, Kansas City

All Listed Sponsors
lead

Children's Mercy Hospital Kansas City

OTHER

NCT04697888 - Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease | Biotech Hunter | Biotech Hunter